Abstract
During the last decade, transcatheter aortic valve implantation (TAVI) has become a widespread procedure for the treatment of symptomatic severe aortic stenosis in patients with high surgical risk. In conjunction with the growing experience, the adverse outcomes of TAVI have arisen, including transcatheter aortic valve infective endocarditis (TAVIE). Although rare, TAVIE has been shown as a major etiology of transcatheter aortic valve failure and its magnitude is expected to increase as TAVI will become more frequent, and long term follow-ups will accumulate. To date, large scale TAVI cohorts have restrictively addressed TAVIE-related data and details regarding TAVIE course and management are available only in sporadic case reports, which have been recently collected and published. In this review, we present a case of TAVIE from our institution and analyze the available data regarding prevalence, clinical presentation and microbiology of TAVIE, as depicted from the current literature. We discuss TAVIE treatment and prophylaxis strategies, which are expected to gain growing attention in the years to come, as TAVI will be established as a key procedure in aortic stenosis management.
Keywords: Transcatheter aortic valve implantation, infective endocarditis, management, prophylaxis.
Current Pharmaceutical Design
Title:Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Volume: 22 Issue: 13
Author(s): Jeremy Ben-Shoshan, Sharon Amit and Ariel Finkelstein
Affiliation:
Keywords: Transcatheter aortic valve implantation, infective endocarditis, management, prophylaxis.
Abstract: During the last decade, transcatheter aortic valve implantation (TAVI) has become a widespread procedure for the treatment of symptomatic severe aortic stenosis in patients with high surgical risk. In conjunction with the growing experience, the adverse outcomes of TAVI have arisen, including transcatheter aortic valve infective endocarditis (TAVIE). Although rare, TAVIE has been shown as a major etiology of transcatheter aortic valve failure and its magnitude is expected to increase as TAVI will become more frequent, and long term follow-ups will accumulate. To date, large scale TAVI cohorts have restrictively addressed TAVIE-related data and details regarding TAVIE course and management are available only in sporadic case reports, which have been recently collected and published. In this review, we present a case of TAVIE from our institution and analyze the available data regarding prevalence, clinical presentation and microbiology of TAVIE, as depicted from the current literature. We discuss TAVIE treatment and prophylaxis strategies, which are expected to gain growing attention in the years to come, as TAVI will be established as a key procedure in aortic stenosis management.
Export Options
About this article
Cite this article as:
Ben-Shoshan Jeremy, Amit Sharon and Finkelstein Ariel, Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151229102028
DOI https://dx.doi.org/10.2174/1381612822666151229102028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem
Infectious Disorders - Drug Targets High-Level Aminoglycoside Resistance in Enterococcus Faecalis and Enterococcus Faecium; as a Serious Threat in Hospitals
Infectious Disorders - Drug Targets Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Helminth Infections and Cardiovascular Diseases: Toxocara Species is Contributing to the Disease
Current Cardiology Reviews The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry Evaluation of <sup>99m</sup>Technetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis
Current Medical Imaging Bacteriophages and Phage-Derived Proteins – Application Approaches
Current Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update After Dana Point Part I: Epidemiology, Clinical Aspects and Diagnostic Options
Current Cardiology Reviews Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Macrolides Allergy
Current Pharmaceutical Design